The Cancer News

Entries

• PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
  October 10, 2026

  Explore immunotherapy biomarker updates: PD-L1 limits, TMB CheckMate 227 trials, HLA and ctDNA models, and prospectiv...

• Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
  October 09, 2026

  Explore muscle-invasive bladder cancer updates: perioperative EV-Pembro approval, KEYNOTE-B15 data, and IMvigor011 ct...

• Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
  October 07, 2026

  Explore Stage III NSCLC updates: PACIFIC durvalumab data, neoadjuvant chemo-immunotherapy conversion rates, and multi...

• ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
  October 07, 2026

  Explore ER+ breast cancer updates: lidERA giredestrant data, vepdegestrant PROTAC approvals, and SERENA-6 ctDNA-guide...

• A Rare Liver Cancer in a Young Woman Underscores the Need for More Options
  October 07, 2026

  Explore fibrolamellar carcinoma updates: DNAJB1-PRKACA fusion insights, STRIDE regimen challenges, and gemcitabine-ox...

• Targeting Endocrine Resistance: New Sequencing Strategies in Metastatic Breast Cancer
  October 05, 2026

  Explore metastatic breast cancer updates: ESR1 oral SERDs, vepdegestrant PROTAC data, PI3K/AKT inhibitors, and ctDNA-...

• Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
  October 05, 2026

  Explore liver cancer updates: EMERALD-3 TACE plus STRIDE data, TARE practice patterns, and GLP-1 receptor agonist sig...

• Advances in the Management of Lung Cancer in 2025 and 2026
  October 01, 2026

  Explore key advances in SCLC and NSCLC management, including drug approvals, bispecific T-cell engagers, antibody-dru...

• Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
  September 30, 2026

  Explore leptomeningeal disease updates: EGFR/ALK targeted therapies, NCCN CSF ctDNA testing guidelines, and proton cr...

• Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
  September 28, 2026

  Explore multiple myeloma updates: CAR-T vs. bispecific sequencing, T-cell exhaustion factors, IVIG infection prophyla...

• At-Home Cervical Cancer Screening Kits Outperform Office-Based Approach in Under-Resourced Settings
  September 21, 2026

  New research from MD Anderson finds mailed HPV screening kits more effective than clinic-based exams, offering a game...

• Precision Frontiers in Hepatobiliary Oncology: FGFR2 Selectivity and Immunotherapy in HCC and iCCA
  September 19, 2026

  Explore how FGFR2-selective therapy is reshaping iCCA treatment and why immunotherapy strategies in HCC are shifting ...

• Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
  September 17, 2026

  Explore multiple myeloma updates: ASCT role in the PERSEUS quadruplet era, MRD-guided maintenance, and CAR-T/bispecif...

• Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
  September 17, 2026

  Meta Description Explore head and neck cancer updates: KEYNOTE-689 perioperative pembrolizumab, NIVOPOSTOP data, and ...

• Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
  September 17, 2026

  Explore prostate cancer updates: perioperative apalutamide in PROTEUS, TALAPRO-3 talazoparib HRR/ATM data, ARPI cogni...

• Overcoming Language Barriers in Cancer Care
  September 15, 2026

  Language barriers delay cancer diagnoses and lower screening rates. Experts explain why interpreter access and cultur...

• The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies.
  September 15, 2026

  Explore lung cancer data: adjuvant selpercatinib in RET+ NSCLC, ANVIL trial limits, and bispecific antibodies (tarlat...

• MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
  September 15, 2026

  Explore high-risk MDS, MECOM-rearranged AML, and BPDCN data: VERONA trial venetoclax results, transplant roles, and e...

• Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Pausing Treatment
  September 15, 2026

  Explore ASCO 2026 prostate cancer updates: perioperative apalutamide, PTEN and HRR biomarker regimens, and data suppo...

• Multiple Myeloma at ASCO 2026: Bispecifics, CELMoDs, In Vivo CAR-T, and Smoldering Disease Care
  September 15, 2026

  Discover ASCO 2026 multiple myeloma breakthroughs, including early teclistamab, mezigdomide CELMoD data, in vivo CAR-...